Skip to main content
Log in

Neopterin

A tumor marker in colorectal carcinoma?

  • Published:
Diseases of the Colon & Rectum

Abstract

Neopterin is compared with other tumor markers in colorectal carcinoma. Its sensitivity is clearly lower than that of CEA, TPA and CA 19/9 and is even lower than the sensivity of the erythrocyte sedimentation rate. The ability of neopterin to discriminate between different tumor stages is also lower than that of the other markers. The discriminant analysis shows that measurement of neopterin in the serum of patients with colorectal carcinoma gives no essential additional information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surg 1984;8:279–86.

    Article  PubMed  CAS  Google Scholar 

  2. Heptner G, Domschke S, Krapf F, Schneider MU, Iro H, Domschke W. Vergleich der Tumormarker CEA und CA 19/9 in der kolorektalen Diagnostik. Dtsch Med Wochenschr 1984;109:1309–12.

    Article  PubMed  CAS  Google Scholar 

  3. Lunde OC, Havig O. Clinical significance of carcinoembryonic antigen (CEA) in patients with adenocarcinoma in colon and rectum. Acta Chir Scand 1982;148:189–93.

    PubMed  CAS  Google Scholar 

  4. Mross KB, Wolfrum DI, Rauschecker H. Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls. Oncology 1985;42:288–95.

    Article  PubMed  CAS  Google Scholar 

  5. Putzki H, Student A, Jablonski M, Heymann H. Comparison of the tumor markers CEA, TPA and CA19/9 in colorectal carcinoma. Cancer 1987;59:223–6.

    Article  PubMed  CAS  Google Scholar 

  6. Quentmeier A, Schlag P, Herfarth C. Schlüsselrolle des CEA-Testes für die Diagnostik des rezidivierten colorectalen Carcinoms. Chirurg 1986;57:83–7.

    PubMed  CAS  Google Scholar 

  7. Wedell J, Meier zu Eissen P, Luu TH, et al. A retrospective study of serial CEA determinations in the early detection of recurrent colorectal cancer. Dis Colon Rectum 1981;24:618–21.

    PubMed  CAS  Google Scholar 

  8. Staab HJ, Brümmendorf T, Hornung A, Kieninger G. The clinical validity of circulating tumor-associated antigens primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochenschr 1985;63:106–15.

    Article  PubMed  CAS  Google Scholar 

  9. Wachter H, Hausen A, Grassmary K. Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Z Physiol Chem 1979;360:1957–60.

    CAS  Google Scholar 

  10. Bichler A, Fuchs D, Hausen A, Hetzel H, König K, Wachter H. Urinary neopterine excretion in patients with genital cancer. Clin Biochem 1982;15:38–40.

    Article  PubMed  CAS  Google Scholar 

  11. Stea B, Halpern RM, Halpern BC, Smith RA. Urinary excretion levels of unconjugated pterins in cancer patients and normal individuals. Clin Chim Acta 1981;113:231–42.

    Article  PubMed  CAS  Google Scholar 

  12. Rokos K, Rokos H, Frisius H. Pteridines as tumor markers? Attempt of evaluation by HPLC and a radioimmunoassay for neopterin. In: Wachter H, Curtius HC, Pfleiderer W, eds. Biochemical and clinical aspects of pteridines. Berlin: de Gruyter, 1982:1:117–30.

    Google Scholar 

  13. Hausen A, Wachter H. Pteridines in the assessment of neoplasia. J Clin Chem Clin Biochem 1982;20:593–602.

    PubMed  CAS  Google Scholar 

  14. Huber C, Fuchs D, Niederwieser D, et al. Neopterin, ein neuer biochemischer Marker zur klinischen Erfassung zellularer Immunreaktionen. Klin Wochenschr 1984;62:103–13.

    Article  PubMed  CAS  Google Scholar 

  15. Hausen A, Fuchs D, Reibnegger G, Bichler A, Hetzel H, Wachter H. Neopterin, a biochemical indicator of cellular immune reactions, in the detection and control of patients with neoplastic diseases. Cancer Detect Prev 1985;8:121–8.

    PubMed  CAS  Google Scholar 

  16. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nordström L. Serum levels of prostatic acid phosphatase (PAP) tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma. Scand J. Clin Lab Invest 1985;45 (suppl 179):75–80.

    Google Scholar 

  17. Robertson EA, Zweig MH. Use of receiver operating characteristic curves to evaluate the clinical performance of analytical systems. Clin Chem 1981;27:1569–74.

    PubMed  CAS  Google Scholar 

  18. McNeil B, Keeler E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975;293:211–5.

    Article  PubMed  CAS  Google Scholar 

  19. Solberg HE. Discriminant analysis in clinical chemistry. Scand J Clin Lab Invest 1975;35:705–12.

    PubMed  CAS  Google Scholar 

  20. Solberg HE, Skrede S, Blomhoff JP. Diagnosis of liver diseases by laboratory results and discriminant analysis. Scand J Clin Lab Invest 1975;35:713–21.

    PubMed  CAS  Google Scholar 

  21. SPSS Users Guide. New York: McGraw-Hill, 1986.

  22. Dacie JV, Lewis SM. Practical haematology. London: Churchill, 1963:408–10.

    Google Scholar 

  23. Haas R, Gerstner L Radioimmunologische Bestimmung von Neopterin bei Blutspendern. Allerg Immunol 1985;31:179–82.

    CAS  Google Scholar 

  24. Mack TM. The evaluation of immunodiagnostic tests. In: Herberman RB, McIntire KR, eds. Immunodiagnosis of cancer. New York: Dekker, 1979:6–20.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Putzki, H., Aschern, F., Henkel, E. et al. Neopterin. Dis Colon Rectum 30, 879–883 (1987). https://doi.org/10.1007/BF02555429

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02555429

Key words

Navigation